ASCO Connection

July 2017

Issue link:

Contents of this Issue


Page 61 of 67

© 2017 Daiichi Sankyo, Inc. All rights reserved. Printed in US 2017 PP-US-ON-0027 03/17 Primary Endpoint: Event-free Survival (EFS) Secondary Endpoints: Location: North America, Europe, Asia/Other Regions | Identier: NCT02668653 t Overall Survival (OS) t Complete Remission (CR) For more information, please visit:, or Quizartinib is an investigational agent and is not approved by the FDA or other regulatory agencies worldwide as a treatment for any indication. Efficacy and safety have not been established. There is no guarantee that quizartinib will become commercially available. t Composite Complete Remission (CRc) t CR with no evidence of minimal residual disease (MRD) A Phase 3, Randomized, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia Quizartinib Advancement into the Next Generation of Trials for Unmet Needs in AML AML=acute myeloid leukemia; FLT-3=FMS-like tyrosine kinase 3; HSCT=hematopoietic stem cell transplant; ITD=internal tandem duplication; * Cycle 1 consists of 7+3 regimen. Alternate dosing option for Cycle 2 can include a 5 + 2 regimen. ** Daunorubicin / Idarubicin Placebo NEWLY DIAGNOSED FLT3-ITD (+) AML 18-75 years of age ECOG 0-2 N≈536 Quizartinib High-Dose Cytarabine + Quizartinib Cytarabine * + Anthracycline ** + Quizartinib High-Dose Cytarabine + Placebo Cytarabine * + Anthracycline ** + Placebo Induction * (1-2 cycles) Consolidation (up to 4 cycles) and/or HSCT Maintenance (up to 12 cycles) NOW RECRUITING Newly Diagnosed FLT3-ITD (+) AML in Patients aged 18 - 75 Daiichi Sankyo, Inc · 211 Mt. Airy Road · Basking Ridge, NJ 07920-2311 Learn more Scan here & in Patients aged 18 - 75

Articles in this issue

Links on this page

Archives of this issue

view archives of ASCO Connection - July 2017